Silo Pharma (NASDAQ:SILO) Posts Earnings Results

Silo Pharma (NASDAQ:SILO) posted its quarterly earnings data on Friday. The company reported ($0.21) EPS for the quarter, Zacks reports. Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

Silo Pharma Price Performance

Shares of Silo Pharma stock traded down $0.07 during midday trading on Friday, hitting $1.84. The company had a trading volume of 48,855 shares, compared to its average volume of 168,715. Silo Pharma has a 1-year low of $1.10 and a 1-year high of $10.43. The business’s 50 day simple moving average is $1.57 and its two-hundred day simple moving average is $4.37. The stock has a market cap of $2.93 million, a PE ratio of -0.42 and a beta of 0.81.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc. is a development-stage biopharmaceutical company focused on developing therapeutics that combine traditional pharmaceutical approaches with psychedelic research. The company’s programs are intended to address conditions involving pain, inflammation, neurological disorders, and mental health. Silo Pharma’s pipeline has included SP-26, an investigational ketamine-based implant designed to provide sustained drug delivery and being explored for conditions such as fibromyalgia. Its research portfolio has also included intranasal formulations and other therapeutics targeting disorders such as post-traumatic stress disorder and Alzheimer’s disease.